Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

929
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
929
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

314
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
314
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

673
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
673
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

404
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
404
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

761
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
761
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

83
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeat CRP measurements and incident myocardial infarction.

American journal of preventive cardiology·2026
Same author

Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approach.

Frontiers in tuberculosis·2026
Same author

Effect of biofilm formation on the antimicrobial activity of tigecycline against <i>Mycobacterium abscessus</i> in the hollow fiber infection model.

Frontiers in microbiology·2026
Same author

Dialysis Modality, Adequacy and the ESRD Quality Incentive Program Score.

Kidney medicine·2026
Same author

Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial.

Clinical pharmacology in drug development·2026
Same author

Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.

Clinical pharmacology in drug development·2026
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis
08:43

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis

Published on: May 11, 2017

13.1K

Pattern Recognition in Pharmacokinetic Data Analysis.

Johan Gabrielsson1, Bernd Meibohm2, Daniel Weiner3

  • 1Department of Biomedical Sciences and Veterinary Public Health, SLU, Division of Pharmacology and Toxicology, Box 7028, SE-750 07, Uppsala, Sweden. johan.gabrielsson@slu.se.

The AAPS Journal
|September 5, 2015
PubMed
Summary
This summary is machine-generated.

This study introduces a formal strategy for pattern recognition in pharmacokinetic data analysis. It helps scientists build better kinetic models by understanding concentration-time data shapes.

Keywords:
absorptionarea under the curvebi-exponentialhalf-lifeinductionintravenous and extravascular dosinglag timemono-exponentialmulti-compartmentnonlinear eliminationplasma concentration-time coursestarget-mediated drug dispositiontransporters

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis
08:43

PTR-ToF-MS Coupled with an Automated Sampling System and Tailored Data Analysis for Food Studies: Bioprocess Monitoring, Screening and Nose-space Analysis

Published on: May 11, 2017

13.1K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Data Analysis and Modeling

Background:

  • Pattern recognition is crucial for selecting pharmacokinetic models.
  • Current methods for exploratory data analysis (EDA) in pharmacokinetics lack formal strategies.
  • Identifying patterns in concentration-time data is key to understanding kinetic processes.

Purpose of the Study:

  • To propose a formal strategy for pattern recognition in pharmacokinetic data analysis.
  • To identify key properties of kinetic models by analyzing concentration-time data patterns.
  • To provide a systematic approach for exploratory data analysis in pharmacokinetics.

Main Methods:

  • Extending existing relationships to calculate potential model parameters using all concentration-time courses.
  • Proposing a checklist for EDA, including analysis of phases, baseline, time delays, dose-dependent shifts, and nonlinearities.
  • Developing equations to model observed patterns in concentration-time data.

Main Results:

  • A structured approach to dissecting concentration-time data patterns is presented.
  • The method aids in identifying model parameters and potential nonlinear behaviors.
  • The proposed strategy facilitates a deeper understanding of kinetic model determinants.

Conclusions:

  • Practicing pattern recognition significantly enhances the quality and efficiency of pharmacokinetic data analysis and model building.
  • This approach leads to a more comprehensive understanding of concentration-time profiles.
  • The proposed strategy offers a rigorous framework for kinetic modeling.